
NanoVibronix NAOV
Quarterly report 2025-Q3
added 11-14-2025
NanoVibronix Gross Profit 2011-2026 | NAOV
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit NanoVibronix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.51 M | 1.54 M | 167 K | 770 K | 214 | 281 K | 160 K | 151 K | 141 K | 98 K | 110 K | 120 K | 116 K | 65 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.54 M | 214 | 373 K |
Quarterly Gross Profit NanoVibronix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 189 K | -35 K | 369 K | - | 133 K | 428 K | 664 K | - | 349 K | 216 K | 235 K | - | 80 K | 281 K | 106 K | - | 228 K | 208 K | 77 K | - | 99 K | 38 K | 51 K | - | 47 K | 207 K | 53 K | - | 8 K | 77 K | 55 K | - | 43 K | 34 K | 36 K | - | 34 K | 40 K | 30 K | - | 30 K | 24 K | 19 K | - | -10 K | 39 K | -40 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 664 K | -40 K | 123 K |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AdaptHealth Corp.
AHCO
|
89.3 M | $ 12.24 | 1.7 % | $ 1.65 B | ||
|
Apyx Medical Corporation
APYX
|
33 M | $ 3.84 | 4.21 % | $ 158 M | ||
|
Alphatec Holdings
ATEC
|
532 M | $ 10.96 | 1.2 % | $ 1.64 B | ||
|
AxoGen
AXGN
|
167 M | $ 33.3 | -3.31 % | $ 1.53 B | ||
|
Butterfly Network
BFLY
|
48.8 M | $ 4.09 | -0.61 % | $ 866 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | ||
|
Bruker Corporation
BRKR
|
1.65 B | $ 36.54 | -0.58 % | $ 5.44 K | ||
|
Boston Scientific Corporation
BSX
|
13.9 B | $ 62.41 | -0.65 % | $ 92.4 B | ||
|
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
22.7 M | $ 9.32 | -0.48 % | $ 264 M | ||
|
CONMED Corporation
CNMD
|
750 M | $ 34.67 | -0.34 % | $ 1.08 B | ||
|
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | ||
|
Cytosorbents Corporation
CTSO
|
26.5 M | $ 0.6 | 2.73 % | $ 37.3 M | ||
|
Delcath Systems
DCTH
|
73.4 M | $ 9.76 | 1.35 % | $ 350 M | ||
|
EDAP TMS S.A.
EDAP
|
24.4 M | $ 3.43 | 1.18 % | $ 128 M | ||
|
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | ||
|
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 80.92 | -0.16 % | $ 47.3 B | ||
|
FONAR Corporation
FONR
|
42.4 M | $ 18.59 | - | $ 122 M | ||
|
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | ||
|
Globus Medical
GMED
|
719 M | $ 87.63 | -0.33 % | $ 11.8 B | ||
|
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | ||
|
Align Technology
ALGN
|
2.8 B | $ 170.68 | 0.05 % | $ 12.8 B | ||
|
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | ||
|
Helius Medical Technologies
HSDT
|
61 K | $ 1.87 | 0.54 % | $ 1.14 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 9.34 | -1.99 % | $ 719 M | ||
|
Inogen
INGN
|
154 M | $ 6.41 | 3.14 % | $ 171 M | ||
|
IRIDEX Corporation
IRIX
|
19.2 M | $ 0.99 | 1.0 % | $ 16.8 M | ||
|
IRadimed Corporation
IRMD
|
64.3 M | $ 97.04 | 0.84 % | $ 1.23 B | ||
|
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | ||
|
Integer Holdings Corporation
ITGR
|
500 M | $ 85.1 | -2.01 % | $ 2.96 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
173 M | $ 15.9 | -1.0 % | $ 373 M | ||
|
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | ||
|
LENSAR
LNSR
|
14.1 M | $ 6.01 | -0.91 % | $ 71.9 M | ||
|
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.39 | 4.14 % | $ 56.6 M | ||
|
Medtronic PLC
MDT
|
19.6 B | $ 86.29 | -0.39 % | $ 111 B | ||
|
MiMedx Group
MDXG
|
346 M | $ 3.86 | -1.53 % | $ 570 M |